SDTM Issue: Can we revise the rules for TIG that EX is not expected, but that EC can be submitted instead of EX since typically only the amount of product used is supplied. EX is to be used when an actual "nicotine" exposure are provide as the dose. Additionally, when pharmaceutical drugs are used then the EC/EX rules in SDTM are followed-. We have no issues, because the treatment is not nicotine.
Assumption for the SDTMIG that may be of concern.
- The EX domain is required for all studies that include protocol-specified study treatment. Exposure records may be directly or indirectly determined; metadata should describe how the records were derived. Common methods for determining exposure (from most direct to least direct) include the following:
- Derived from actual observation of the administration of drug by the investigator
- Derived from automated dispensing device that records administrations
- Derived from subject recall
- Derived from product accountability data
- Derived from the protocol. When a study is still masked and protocol-specified study treatment doses cannot yet be reflected in the protocol-specified unit due to blinding requirements, then the EX domain is not expected to be populated.
Nicotine replacement therapy (NRT) comes in a variety of forms that are used in different ways. It is available as skin patches, chewing gum, nasal and oral sprays, inhalers, lozenges and tablets.
Vapes, vaporizers, vape pens, hookah pens, electronic cigarettes (e-cigarettes or e-cigs), e-cigars, and e-pipes are some of the many tobacco product terms used to describe electronic nicotine delivery systems (ENDS). These products use an “e-liquid” that usually contains nicotine derived from tobacco, as well as flavorings, propylene glycol, vegetable glycerin, and other ingredients. The liquid is heated to create an aerosol that the user inhales.
Self-report of nicotine exposure often may be biased and lead to inaccurate measures of exposure. Hence, biomarkers are often used to provide objective measure of nicotine exposure. Studies on tobacco product typically collect the quantities of the tobacco product used through self-reporting, while the actual nicotine exposure is measured by biomarkers.
The Exposure as collected (EC) domain is used to reflect amounts at the product-level (e.g., number or cigarettes, number of cartridges, number of patches etc and not the actual exposure to the product. The actual exposure to the product would be represented in EX. The actual exposure is typically derived from EC, DA and the protocol-specific details on the study product used. Product accountability details (e.g., amount dispensed, amount returned) are represented in the Product Accountability Domain (DA) domain, and not in EC or EX.
The degree of summarization of records from EC to EX is sponsor-defined and is used to support study purpose and analysis. EX derivations must be described in the Define-XML document. The summarization may also be performed in ADaM.
Overview
Content Tools